FGFR2 and cholangiocarcinoma: In 2019, the first approved targeted therapy for locally advanced or metastatic intrahepatic CCA was pemigatinib, an inhibitor of fibroblast growth factor receptor 2 (FGFR2) gene fusions or rearrangements [107,108].